Virologica Sinica

, Volume 26, Issue 6, pp 357–365 | Cite as

Ribosome inactivating proteins from plants inhibiting viruses

  • Inderdeep Kaur
  • R. C. Gupta
  • Munish Puri


Many plants contain ribosome inactivating proteins (RIPs) with N-glycosidase activity, which depurinate large ribosomal RNA and arrest protein synthesis. RIPs so far tested inhibit replication of mRNA as well as DNA viruses and these proteins, isolated from plants, are found to be effective against a broad range of viruses such as human immunodeficiency virus (HIV), hepatitis B virus (HBV) and herpes simplex virus (HSV). Most of the research work related to RIPs has been focused on antiviral activity against HIV; however, the exact mechanism of antiviral activity is still not clear. The mechanism of antiviral activity was thought to follow inactivation of the host cell ribosome, leading to inhibition of viral protein translation and host cell death. Enzymatic activity of RIPs is not limited to depurination of the large rRNA, in addition they can depurinate viral DNA as well as RNA. Recently, Phase I/II clinical trials have demonstrated the potential use of RIPs for treating patients with HIV disease. The aim of this review is to focus on various RIPs from plants associated with anti-HIV activity.

Key words

Ribosome inactivating protein Human immunodeficiency virus Hepatitis B virus Herpes simplex virus 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Barbieri L, Ferreras J M, Barraco A, et al. 1992. Some ribosome-inactivating proteins depurinate ribosomal RNA at multiple sites. Biochem J, 286: 1–4.PubMedGoogle Scholar
  2. 2.
    Bica I, McGovern B, Dhar R, et al. 2001. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dise, 132: 492–497.CrossRefGoogle Scholar
  3. 3.
    Bourinbaiar A S, Huang S L. 1996. The activity of plant-derived antiretroviral proteins MAP30 and GAP31 against Herpes Simplex Virus infection in vitro. Biochem Biophys Res Commun, 219: 923–929.PubMedCrossRefGoogle Scholar
  4. 4.
    Byers V S, Levin A S, Waites L A, et al. 1990. A phase I/II study of trichosanthin treatment of HIV disease. AIDS, 4: 1189–1196.PubMedCrossRefGoogle Scholar
  5. 5.
    D’cruz O J, Uckun F M. 2001. Pokeweed antiviral protein: a potential nonspermicidal prophylactic antiviral agent. Fertil Steril, 75: 106–114.PubMedCrossRefGoogle Scholar
  6. 6.
    Fan J M, Zhang Q, Xu J, et al. 2009. Inhibition on hepatitis B virus in vitro of recombinant MAP30 from bitter melon. Mol Biol Rep, 36: 381–388.PubMedCrossRefGoogle Scholar
  7. 7.
    He Y W, Guo C X, Pan Y F. 2008. Inhibition of hepatitis B virus replication by pokeweed antiviral protein. World J Gastroenterol, 14: 1592–1597.PubMedCrossRefGoogle Scholar
  8. 8.
    Huang H, Chan H, Wang Y Y, et al. 2006. Trichosanthin suppress the elevation of p38 MAPK and Bcl-2 induced by HSV-1 infection in Vero cells. Life Sci, 13: 1287–1292.CrossRefGoogle Scholar
  9. 9.
    Huang P L, Sun Y, Chen H C, et al. 1999. Proteolytic fragments of anti-HIV and anti-tumor proteins MAP30 an GAP31 are biologically active. Biochem Biophys Res Commun, 262: 615–623.PubMedCrossRefGoogle Scholar
  10. 10.
    Kahn J O, Gorelick K J, Gatti G, et al. 1994. Safety, activity and pharmacokinetics of GLQ223 in patients with AIDS and AIDS-related complex. Antimicrob Agents Ch, 38: 260–267.Google Scholar
  11. 11.
    Kaur I, Yadav SK, Puri M, et al. 2011. Balsamin, a novel ribosome inactivating protein from the seeds of Balsam apple Momordica balsamina. Amino Acids (accepted).Google Scholar
  12. 12.
    Lee Huang S, Huang P L, Chen H C, et al. 1995a. Anti-HIV and anti-tumor activities of recombinant MAP30 from bitter melon. Gene, 161: 151–156.PubMedCrossRefGoogle Scholar
  13. 13.
    Lee Huang S, Huang P L, Huang P L, et al. 1995b. Inhibition of the integrase of human immunodeficiency (HIV) type I by anti-HIV plant proteins MAP30 and GAP31. Proc Natl Acad Sci USA, 92: 8818–8822.PubMedCrossRefGoogle Scholar
  14. 14.
    Lee Huang S, Huang P L, Nara P L, et al. 1990. MAP30: a new inhibitor of HIV-1 infection and replication. FEBS Lett, 272: 12–18.PubMedCrossRefGoogle Scholar
  15. 15.
    Mansouri S, Choudhary G, Sarzala P M. 2009. Suppression of human T-cell leukemia virus I gene expression by pokeweed antiviral protein. J Biol Chem, 284: 31453–31462.PubMedCrossRefGoogle Scholar
  16. 16.
    McGrath M S, Hwang K M, Cladwell S E, et al. 1989. GLQ223: an inhibitor of human immunodeficiency virus replication in acutely and chronically infected cells of lymphocyte and mononuclear phagocyte linege. Proc Natl Acad Sci USA, 86: 2844–2848.PubMedCrossRefGoogle Scholar
  17. 17.
    Narouz N, Allan P S, Wade A H, et al. 2003. Genital herpes serptestinh: a study of the epidemiology and patient knowledge and attitude among STD clinic attnders in conventry, UK. Sex Transum Infect, 79: 35–41.CrossRefGoogle Scholar
  18. 18.
    Nugier F, Colin J N, Aymard M, et al. 1992. Occurrence and characterization of acyclovir-resistant herpes simplex virus isolates: report on a two-year sensitivity screening survey. J Med Virol, 36:1–12.PubMedCrossRefGoogle Scholar
  19. 19.
    Peumans, W J, Hao Q, Van Damme E J M. 2001. Ribosome inactivating proteins from plants: more than RNA N-glycosidase? FASEB J, 15: 1493–1506.PubMedCrossRefGoogle Scholar
  20. 20.
    Puri, M, Kaur I, Kanwar R K, et al. 2009 Ribosome inactivating protein (RIPs) from Momordica charantia for antiviral therapy. Curr Mol Med, 9: 1080–1094.PubMedCrossRefGoogle Scholar
  21. 21.
    Puri, M. 2010. Biotechnological potential of Momordica balsamina revealed. Curr Pharma Biotechnol, 11, 229CrossRefGoogle Scholar
  22. 22.
    Rajamohan F, Venkatachalam T K, Irvin J D, et al. 1999. Pokeweed antiviral protein isoforms PAP-I, PAP-II and PAP-III depurinate RNA of human immunodeficiency virus (HIV-1). Biochem Biophys Res Commun, 260: 453–458.PubMedCrossRefGoogle Scholar
  23. 23.
    Sawasaki T, Morishita R, Ozawa A, et al. 1999. Mechanism of ribosome RNA apurinic site specific lyase. Nucleic Acids Symp Ser, 42: 257–258.PubMedGoogle Scholar
  24. 24.
    Stripe F, Battelli M G. 2006. Ribosome-inactivating proteins: progress and problems. Cell Mol Life Sci, 63: 1850–1866.CrossRefGoogle Scholar
  25. 25.
    Stripe F. 2004. Ribosome-inactivating proteins. Toxins, 44: 371–383.Google Scholar
  26. 26.
    Taylor G P, Matsuoka M. 2005. Natural history of adult T-cell leukemia/lymphoma and approaches to therapy. Oncogne, 24: 6047–6057.CrossRefGoogle Scholar
  27. 27.
    Uckun F M, Bellong K, O’ Neill K, et al. 1999. Toxicity, Biologcal activity and pharmacokinetic of TXU (Anti-CD)7-pokeweed antiviral protein in chimpanzees and adult patients infected with human immunodeficiency virus. J Pharmacol Exp Ther, 291: 1301–1307.PubMedGoogle Scholar
  28. 28.
    Uckun F M, Chelstrom L M, Ahlgren L T, et al. 1998. TXU (Anti-CD7)-pokeweed antiviral protein as a potent inhibitor of human immunodeficiency virus. Antimicrob Agents Ch, 47: 1052–1061.CrossRefGoogle Scholar
  29. 29.
    Uckun F M, Rajamohan F, Pendergrass S, et al. 2003. Structure-based design and engineering of a non-toxic recombinant pokeweed antiviral protein with potent anti-human immunodeficiency virus activity. Antimicrob Agents Ch, 47: 1052–1061.CrossRefGoogle Scholar
  30. 30.
    Wang J H, Nie H L, Tam S C, et al. 2002. Anti-HIV-1 property of trichosanthin correlates with its ribosome inactivating activity. FEBS Lett, 531: 295–298.PubMedCrossRefGoogle Scholar
  31. 31.
    Zarling J M, Moran P A, Haffar O, et al. 1990. Inhibition of HIV replication by pokeweed antiviral protein targeted to CD4+ cells by monoclonal antibodies. Nature, 347: 92–95.PubMedCrossRefGoogle Scholar
  32. 32.
    Zhao W L, Feng D, Wu J, et al. 2010. Trichosanthin inhibits integration of human immunodeficiency virus type I trough depurinating the long-terminal repeats. Mol Biol Rep, 37:2093–2098.PubMedCrossRefGoogle Scholar
  33. 33.
    Zhao W, Feng D, Sun S, et al. 2010. The aniviral protein of trichosanthin penetrates into human immunodeficiency virus type I. Acta Biochim Biophys Sin, 42: 91–97.PubMedCrossRefGoogle Scholar

Copyright information

© Wuhan Institute of Virology, CAS and Springer-Verlag Berlin Heidelberg 2011

Authors and Affiliations

  1. 1.Centre for Biotechnology and Interdisciplinary Science (BioDeakin), Institute of Technology Research and Innovation (ITRI)Deakin UniversityVictoriaAustralia
  2. 2.Protein and Fermentation Biotechnology Laboratory, Department of BiotechnologyPunjabi UniversityPatialaIndia
  3. 3.Department of BotanyPunjabi UniversityPatialaIndia

Personalised recommendations